BioVie (BIVI) News Today $3.91 -1.05 (-21.17%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$4.33 +0.42 (+10.77%) As of 04:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIVI Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and ...August 6 at 2:46 AM | theglobeandmail.comBioVie (NASDAQ:BIVI) Stock Price Down 1.8% - Here's What HappenedJuly 30, 2025 | americanbankingnews.comBiovie stock rises after drug shows age deceleration in Alzheimer’s patientsJuly 24, 2025 | investing.comBiovie shares climb as Alzheimer’s drug shows promising age deceleration effectsJuly 24, 2025 | msn.comBioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and GerontologyJuly 24, 2025 | globenewswire.comBioVie Inc. Appoints Dr. Amy S. Chappell and Kameel D. Farag to Board of DirectorsJuly 22, 2025 | quiverquant.comQBioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of DirectorsJuly 22, 2025 | globenewswire.comBioVie Inc. Presents Promising Data on Bezisterim's Effects on Aging ...July 11, 2025 | nasdaq.comBIVI - BioVie Inc Ordinary Shares - Class A Chart - MorningstarJuly 2, 2025 | morningstar.comMBioVie Inc. Presents Patient-Centric Design of SUNRISE-PD Phase 2 Clinical Trial at Advanced Therapeutics in Movement & Related Disorders CongressJune 26, 2025 | quiverquant.comQBioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)June 26, 2025 | globenewswire.comBioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® CongressJune 24, 2025 | globenewswire.comBioVie Inc Ordinary Shares - Class AMay 23, 2025 | morningstar.comMBioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025May 14, 2025 | globenewswire.comBIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmApril 30, 2025 | globenewswire.comBioVie initiates SUNRISE-PD trial assessing BezisterimApril 17, 2025 | markets.businessinsider.comBioVie, Inc.: BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient EnrolledApril 16, 2025 | finanznachrichten.deBioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient EnrolledApril 16, 2025 | markets.businessinsider.comBioVie Inc. (BIVI) Stock Price, News, Quote & History - Yahoo FinanceApril 2, 2025 | finance.yahoo.comBioVie announces board member resignationMarch 30, 2025 | uk.investing.comBioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025March 27, 2025 | globenewswire.comBioVie initiated with a Buy at BrooklineMarch 20, 2025 | markets.businessinsider.comIs BioVie (NASDAQ:BIVI) In A Good Position To Invest In Growth?February 13, 2025 | finance.yahoo.comBioVie partners with New to The Street for media campaignJanuary 13, 2025 | markets.businessinsider.comBIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJanuary 2, 2025 | globenewswire.comBioVie files to sell 7.71M shares of common stock for holdersNovember 22, 2024 | markets.businessinsider.comBioVie says Parkinson’s Disease clinical trial is fully fundedNovember 5, 2024 | markets.businessinsider.comBioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully FundedNovember 5, 2024 | theglobeandmail.comBioVie Inc. Announces Closing of Registered Direct OfferingOctober 31, 2024 | tmcnet.comBioVie Raises Capital Through Direct Stock OfferingOctober 30, 2024 | msn.comBioVie Raises $3.24 Million in Direct OfferingOctober 30, 2024 | markets.businessinsider.comBioVie 1.15M share registered direct offering priced at $2.83October 29, 2024 | markets.businessinsider.comUPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq RulesOctober 28, 2024 | globenewswire.comBioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq RulesOctober 28, 2024 | globenewswire.comBioVie Inc. (NASDAQ:BIVI) Short Interest UpdateOctober 26, 2024 | marketbeat.comBioVie Announces $6 Million Stock Offering and PlacementOctober 25, 2024 | markets.businessinsider.comBioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private PlacementOctober 24, 2024 | globenewswire.comBioVie 2.667M share registered direct offering priced at $2.25October 24, 2024 | markets.businessinsider.comBioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesOctober 23, 2024 | globenewswire.comBioVie Secures $6.66 Million Through Direct OfferingOctober 23, 2024 | markets.businessinsider.comBioVie Announces Stock Offering and Private PlacementOctober 23, 2024 | finance.yahoo.comBioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private PlacementOctober 22, 2024 | globenewswire.comBioVie stock dips after pricing offering to raise $6.66MOctober 22, 2024 | msn.comBioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesOctober 21, 2024 | globenewswire.comTraders Buy Large Volume of Call Options on BioVie (NASDAQ:BIVI)October 21, 2024 | marketbeat.comBioVie (NASDAQ:BIVI) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comBioVie secures patent for terlipressin formulationOctober 17, 2024 | uk.investing.comBioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of TerlipressinOctober 15, 2024 | globenewswire.comBioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of TerlipressinOctober 2, 2024 | markets.businessinsider.comBioVie Inc. (NASDAQ:BIVI) Sees Large Drop in Short InterestSeptember 29, 2024 | marketbeat.com Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address BIVI Media Mentions By Week BIVI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIVI News Sentiment▼0.000.42▲Average Medical News Sentiment BIVI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIVI Articles This Week▼11▲BIVI Articles Average Week Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NRx Pharmaceuticals News Today Renovaro News Today Alterity Therapeutics News Today RenovoRx News Today Senti Biosciences News Today Exicure News Today Gain Therapeutics News Today Jasper Therapeutics News Today PepGen News Today Eliem Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIVI) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
